Atea Pharmaceuticals (AVIR) Competitors $3.37 +0.04 (+1.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVIR vs. BCYC, NTLA, RCKT, ZYME, ADPT, GYRE, PSTX, OCS, NUVB, and AVXLShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Bicycle Therapeutics (BCYC), Intellia Therapeutics (NTLA), Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Bicycle Therapeutics Intellia Therapeutics Rocket Pharmaceuticals Zymeworks Adaptive Biotechnologies Gyre Therapeutics Poseida Therapeutics Oculis Nuvation Bio Anavex Life Sciences Bicycle Therapeutics (NASDAQ:BCYC) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment. Do institutionals & insiders hold more shares of BCYC or AVIR? 86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 8.5% of Bicycle Therapeutics shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer BCYC or AVIR? Bicycle Therapeutics received 120 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 70.41% of users gave Bicycle Therapeutics an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBicycle TherapeuticsOutperform Votes13870.41% Underperform Votes5829.59% Atea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Is BCYC or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -450.64%. Bicycle Therapeutics' return on equity of -27.35% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-450.64% -27.35% -20.81% Atea Pharmaceuticals N/A -34.90%-32.38% Which has higher earnings and valuation, BCYC or AVIR? Atea Pharmaceuticals has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$26.98M34.14-$180.66M-$3.29-4.05Atea PharmaceuticalsN/AN/A-$135.96M-$2.07-1.63 Does the media prefer BCYC or AVIR? In the previous week, Bicycle Therapeutics had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 19 mentions for Bicycle Therapeutics and 6 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.97 beat Bicycle Therapeutics' score of 0.39 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BCYC or AVIR? Bicycle Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Do analysts recommend BCYC or AVIR? Bicycle Therapeutics currently has a consensus price target of $34.50, indicating a potential upside of 158.62%. Atea Pharmaceuticals has a consensus price target of $6.88, indicating a potential upside of 104.15%. Given Bicycle Therapeutics' higher probable upside, research analysts clearly believe Bicycle Therapeutics is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryBicycle Therapeutics and Atea Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.19M$6.35B$5.21B$8.94BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-1.639.8589.7217.34Price / SalesN/A315.771,249.2477.44Price / CashN/A61.4443.8235.97Price / Book0.516.055.324.79Net Income-$135.96M$154.90M$122.69M$225.00M7 Day Performance3.06%-1.70%-0.16%1.52%1 Month Performance7.67%1.93%3.50%4.88%1 Year Performance-5.60%3.14%25.80%20.12% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals3.871 of 5 stars$3.37+1.2%$6.88+104.2%-5.6%$276.19MN/A-1.6370Short Interest ↓News CoverageGap UpBCYCBicycle Therapeutics3.2885 of 5 stars$15.12+13.6%$34.50+128.2%-24.8%$1.04B$36.90M-4.60240Short Interest ↑Analyst RevisionPositive NewsNTLAIntellia Therapeutics4.4861 of 5 stars$10.09-1.1%$51.56+411.0%-62.4%$1.03B$43.09M-1.85600Analyst ForecastNews CoverageRCKTRocket Pharmaceuticals4.5012 of 5 stars$10.75-3.5%$47.27+339.7%-60.6%$979.94MN/A-3.91240News CoverageZYMEZymeworks3.8142 of 5 stars$13.90+5.1%$19.17+37.9%+40.8%$957.40M$62.20M-9.27290Insider TradePositive NewsADPTAdaptive Biotechnologies2.6215 of 5 stars$6.47-0.5%$6.75+4.3%+67.3%$954.84M$177.28M-4.83790News CoverageGYREGyre Therapeutics0.3144 of 5 stars$9.96-0.3%N/A-47.4%$931.47M$105.03M0.0040Short Interest ↑News CoveragePSTXPoseida Therapeutics3.2292 of 5 stars$9.50flat$9.50N/A$928.85M$150.86M-15.08260OCSOculis2.4546 of 5 stars$22.12+4.6%$28.80+30.2%+107.9%$895.95M$980,000.00-11.462Short Interest ↑Gap UpNUVBNuvation Bio2.393 of 5 stars$2.66-4.3%$7.40+178.2%+67.0%$895.27M$2.16M-1.2360Short Interest ↑Gap DownAVXLAnavex Life Sciences3.6923 of 5 stars$10.55-6.1%$44.00+317.1%+53.2%$894.81MN/A-21.1040Positive News Related Companies and Tools Related Companies Bicycle Therapeutics Alternatives Intellia Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Zymeworks Alternatives Adaptive Biotechnologies Alternatives Gyre Therapeutics Alternatives Poseida Therapeutics Alternatives Oculis Alternatives Nuvation Bio Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVIR) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts